Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Current Leases: 2020-2024

Historic Current Leases for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to $393,430.

  • SAB Biotherapeutics' Current Leases rose 117.54% to $837,286 in Q3 2025 from the same period last year, while for Sep 2025 it was $837,286, marking a year-over-year increase of 117.54%. This contributed to the annual value of $393,430 for FY2024, which is 41.27% down from last year.
  • SAB Biotherapeutics' Current Leases amounted to $393,430 in FY2024, which was down 41.27% from $669,946 recorded in FY2023.
  • SAB Biotherapeutics' Current Leases' 5-year high stood at $1.1 million during FY2021, with a 5-year trough of $393,430 in FY2024.
  • For the 3-year period, SAB Biotherapeutics' Current Leases averaged around $518,057, with its median value being $490,794 (2022).
  • Its Current Leases has fluctuated over the past 5 years, first tumbled by 57.04% in 2022, then spiked by 36.50% in 2023.
  • Over the past 5 years, SAB Biotherapeutics' Current Leases (Yearly) stood at $924,265 in 2020, then rose by 23.60% to $1.1 million in 2021, then slumped by 57.04% to $490,794 in 2022, then skyrocketed by 36.50% to $669,946 in 2023, then plummeted by 41.27% to $393,430 in 2024.